Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Charles River Laboratories International Inc. (CRL) delivers vital contract research services that power pharmaceutical discoveries and biotech innovations worldwide. This news hub provides investors and industry professionals with timely updates on CRL's scientific advancements and strategic developments.
Access authoritative coverage of earnings reports, regulatory milestones, and partnership announcements that shape CRL's role in accelerating drug development. Our curated collection includes preclinical research updates, manufacturing compliance achievements, and executive leadership changes impacting the life sciences sector.
Discover comprehensive reporting on:
• Clinical trial support innovations
• Strategic acquisitions in research services
• Regulatory compliance updates
• Financial performance metrics
Bookmark this page for streamlined access to CRL's evolving position in global healthcare research. Verify critical developments through primary-source press releases and expert analysis of market-moving announcements.
Charles River Laboratories reported Q4 2024 revenue of $1.00 billion, down 1.1% from Q4 2023, and full-year 2024 revenue of $4.05 billion, a 1.9% decrease from 2023. The company posted a Q4 GAAP loss per share of $(4.22), primarily due to a $215.0 million non-cash goodwill impairment related to the Biologics Solutions unit.
Full-year 2024 GAAP earnings were $0.20 per share, while non-GAAP earnings reached $10.32 per share. The company's organic revenue declined by 2.8% in 2024. For 2025, Charles River projects an organic revenue decrease of 3.5% to 5.5% and non-GAAP EPS of $9.10 to $9.60.
The company announced plans for $350 million in stock repurchases for 2025. Management noted continued constraints in early-stage spending by global biopharmaceutical clients, while expecting stable to slightly improved demand from small and mid-sized biotechnology clients.
Charles River Laboratories (NYSE: CRL) and Deciphex have announced an expansion of their strategic partnership to advance digital pathology solutions. The collaboration focuses on integrating the Patholytix platform across Charles River's global network to enhance image management, distribution, and archiving workflows in toxicologic pathology.
Building on their successful 2024 launch of Foresight, the partnership aims to develop advanced AI tools for toxicologic pathology, including new screening capabilities for acute toxicity and carcinogenicity studies. The integrated system is expected to streamline digital workflows, reduce turnaround times, and enable better collaboration across global teams.
The partnership combines Deciphex's digital pathology expertise with Charles River's toxicologic pathology network, offering clients enhanced capabilities for primary evaluation and peer review in toxicologic pathology assessment, ultimately accelerating drug development and safety assessment processes.
Charles River Laboratories (NYSE: CRL) has announced it will release its fourth-quarter and full-year 2024 financial results along with 2025 guidance on Wednesday, February 19th, before market opening. The company has scheduled a conference call at 8:30 a.m. ET on the same day to discuss these results.
Investors can access a live webcast of the conference call through the Investor Relations section of the company's website at ir.criver.com. A replay of the call will also be made available through the same platform.
Charles River Laboratories (NYSE: CRL) announced the launch of Apollo™ for CRADL®, a secure cloud-based platform enhancing their vivarium rental services. The platform streamlines research initiation by providing a centralized dashboard connecting clients to online training, research models ordering, and study support services.
Apollo serves as the technology stack driving Charles River's digital transformation, offering expanded client access across their portfolio through multiple integrations:
- Apollo for CRADL: Streamlines administrative tasks for vivarium rental solutions
- Apollo for Safety Assessment: Provides real-time access to data visualization and program planning
- Apollo for Biologics: Centralizes sample submission and tracking
- Apollo for Discovery: Enables instant oncology study price estimates
- Apollo for Logica®: Delivers real-time updates for AI-powered small molecule programs
- Research Models Online Ordering System: Offers interactive catalog with real-time inventory
Charles River Laboratories (NYSE: CRL) and Akron Bio announced the integration of Akron's Closed System Solutions (CSS)™ line of liquid cytokines into Charles River's Cell Therapy Flex Platform for Process Development. This integration aims to enhance closed system processing, streamline operations, and improve process robustness.
The Cell Therapy Flex Platform, designed as an off-the-shelf solution for Cell Therapy Process Development, now incorporates Akron's CGMP liquid cytokines, including rHu IL-2, IL-7, IL-15, and IL-21. These cytokines are available in single-use bags with weldable tubing, maintaining stability at 2-8°C and enabling rapid, aseptic media formulation while minimizing operator error.
This collaboration enhances manufacturing efficiency by decreasing labor requirements and improving process robustness for CAR-T and TCR-T cell therapies development.
Charles River Laboratories (NYSE: CRL) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). The presentation will feature management's overview of the company's strategic focus, business developments, and recent trends.
Investors and interested parties can access a live webcast of the presentation through a link that will be available on the Investor Relations section of Charles River's website at ir.criver.com. A replay of the webcast will be accessible through the same website following the presentation and will remain available for a minimum of two weeks.
Deciphex has secured $32.3 million in Series C funding led by Molten Ventures, with participation from multiple investors including Charles River Laboratories (NYSE: CRL). The funding aims to address the global pathology shortage, where over 70% of healthcare decisions require pathology investigation amid declining pathologist numbers.
The company's AI-powered platforms, Diagnexia and Patholytix, enable pathologists to work up to 40% faster while maintaining diagnostic accuracy. The funding will support global expansion across the US, UK, EU, Canada, and Japan, enhance platform capabilities, accelerate AI foundational model development, strengthen partnerships with industry leaders like Novartis and Charles River Laboratories, and expand services to pharmaceutical, biotech, and CRO clients.
Charles River Laboratories (NYSE: CRL) has launched the Charles River Incubator Program (CIP), aimed at supporting early-stage biotechnology companies in the discovery, development, and manufacturing of advanced therapies. Through its Global Innovation Center of Excellence, CIP offers knowledge, connectivity, and priority access to Charles River's extensive portfolio. This initiative builds on the success of the Cell and Gene Therapy Accelerator Program (CAP), designed to assist companies 18-24 months from Investigational New Drug (IND) or Clinical Trial Application (CTA) submission. CIP targets companies 24+ months from IND or CTA submission, providing regulatory and quality expertise, personnel training, and access to laboratory space and equipment. The Global Innovation Center of Excellence integrates a team of scientific, regulatory, and manufacturing experts to foster innovation and support thousands of IND and CTA submissions. The next cohort will be shortlisted at the Cell and Gene Therapy Summit on March 4, 2025, in San Francisco, CA.
Charles River Laboratories (NYSE: CRL) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. During the event, the management will discuss strategic focus, business developments, and recent trends. A live webcast of the presentation will be accessible via the Investor Relations section of the Charles River website at ir.criver.com. The webcast replay will be available on the same site for at least two weeks post-presentation.
Charles River Laboratories (NYSE: CRL) has announced its upcoming presentations at two major healthcare conferences. The company will present at the UBS Global Healthcare Conference on November 12th at 10:15 a.m. PT and the Jefferies London Healthcare Conference on November 20th at 2:00 p.m. GMT.
Management will discuss the company's strategic focus, business developments, and recent trends. Both presentations will be available via live webcast through the Investor Relations section of Charles River's website, with replays accessible for at least two weeks afterward.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
